JP2008024600A - Inhibitor for acrolein adduct formation, skin anti-aging external preparation and anti-aging food and beverage containing the same - Google Patents
Inhibitor for acrolein adduct formation, skin anti-aging external preparation and anti-aging food and beverage containing the same Download PDFInfo
- Publication number
- JP2008024600A JP2008024600A JP2006195358A JP2006195358A JP2008024600A JP 2008024600 A JP2008024600 A JP 2008024600A JP 2006195358 A JP2006195358 A JP 2006195358A JP 2006195358 A JP2006195358 A JP 2006195358A JP 2008024600 A JP2008024600 A JP 2008024600A
- Authority
- JP
- Japan
- Prior art keywords
- aging
- acrolein
- external preparation
- skin
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 title claims abstract description 79
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 27
- 235000013305 food Nutrition 0.000 title claims abstract description 17
- 230000015572 biosynthetic process Effects 0.000 title claims abstract description 16
- 239000003112 inhibitor Substances 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title abstract description 17
- 235000013361 beverage Nutrition 0.000 title abstract description 8
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims abstract description 24
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 24
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 claims abstract description 22
- 108010024636 Glutathione Proteins 0.000 claims abstract description 12
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 claims abstract description 12
- 235000004515 gallic acid Nutrition 0.000 claims abstract description 12
- 229940074391 gallic acid Drugs 0.000 claims abstract description 12
- 229960003180 glutathione Drugs 0.000 claims abstract description 12
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940074360 caffeic acid Drugs 0.000 claims abstract description 11
- 235000004883 caffeic acid Nutrition 0.000 claims abstract description 11
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 claims abstract description 11
- SHWIJIJNPFXOFS-UHFFFAOYSA-N thiotaurine Chemical compound NCCS(O)(=O)=S SHWIJIJNPFXOFS-UHFFFAOYSA-N 0.000 claims abstract description 11
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 10
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000005487 catechin Nutrition 0.000 claims abstract description 10
- 229950001002 cianidanol Drugs 0.000 claims abstract description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 9
- 235000018417 cysteine Nutrition 0.000 claims description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 abstract description 24
- 102000004169 proteins and genes Human genes 0.000 abstract description 10
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 238000001727 in vivo Methods 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 229960003067 cystine Drugs 0.000 abstract description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 abstract 1
- 230000002000 scavenging effect Effects 0.000 abstract 1
- 235000003969 glutathione Nutrition 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- VEYYWZRYIYDQJM-ZETCQYMHSA-N N(2)-acetyl-L-lysine Chemical compound CC(=O)N[C@H](C([O-])=O)CCCC[NH3+] VEYYWZRYIYDQJM-ZETCQYMHSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- -1 acrolein amino acid Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 description 2
- 102100037209 Peroxisomal N(1)-acetyl-spermine/spermidine oxidase Human genes 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 2
- 235000012734 epicatechin Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 108010089000 polyamine oxidase Proteins 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- KNUPSOXBESCJLY-UHFFFAOYSA-N 2-methoxy-1-phenylhexan-1-one Chemical compound CCCCC(OC)C(=O)C1=CC=CC=C1 KNUPSOXBESCJLY-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 241000208690 Hamamelis Species 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- DCYOADKBABEMIQ-OWMUPTOHSA-N myricitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=C(O)C=2)OC2=CC(O)=CC(O)=C2C1=O DCYOADKBABEMIQ-OWMUPTOHSA-N 0.000 description 1
- DCYOADKBABEMIQ-FLCVNNLFSA-N myricitrin Natural products O([C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O1)C1=C(c2cc(O)c(O)c(O)c2)Oc2c(c(O)cc(O)c2)C1=O DCYOADKBABEMIQ-FLCVNNLFSA-N 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Abstract
Description
本発明は、アクロレインのアミノ酸やタンパク質との付加体形成阻害剤であり、その付加体形成阻害剤を含有する皮膚抗老化外用剤や抗老化用飲食品に関する。 The present invention relates to an acrolein amino acid or protein adduct formation inhibitor, and relates to a skin anti-aging external preparation or anti-aging food or drink containing the adduct formation inhibitor.
従来より、老化を抑制する抗老化剤としては、種々のものが開発されている。生体の老化は、２つの生物学的要因により起こることが知られている。 Conventionally, various anti-aging agents that suppress aging have been developed. It is known that aging of a living body is caused by two biological factors.
１つは生理的老化で、他の１つは紫外線等の被爆部に生じる光老化と呼ばれるものである。生理的老化は、生体内で生成した活性酸素が影響し、血管や皮膚の主な構成因子であるコラーゲン線維の変性や生理機能に係わりの深い酵素の変質による活性の低下などに関わる。光老化に感しては、紫外線への暴露が原因であるため原則的に皮膚に限られる。 One is physiological aging, and the other is called photoaging that occurs in exposed parts such as ultraviolet rays. Physiological aging is influenced by active oxygen generated in the living body, and is related to degeneration of collagen fibers, which are the main components of blood vessels and skin, and a decrease in activity due to alteration of enzymes deeply related to physiological functions. Sensation of photoaging is in principle limited to the skin because it is caused by exposure to ultraviolet rays.
生理的老化において、活性酸素種を除去することが主に検討され、スーパーオキサイドアニオン、ヒドロキシラジカル、一重項酸素、パーオキシナイトライト等に対する除去剤が提示されている。近年、活性酸素以外の老化因子としてアクロレインや４−ヒドロキシノネナールの関与が注目されている。 In physiological aging, removal of reactive oxygen species has been mainly studied, and removal agents for superoxide anion, hydroxy radical, singlet oxygen, peroxynitrite and the like have been proposed. In recent years, the involvement of acrolein and 4-hydroxynonenal has attracted attention as aging factors other than active oxygen.
アクロレインや４-ヒドロキシノネナールはα,β-不飽和アルデヒドで反応性が高く、タンパク質（酵素やコラーゲン）の変性や細胞毒性に関わり、その細胞毒性は類縁のアルデヒドであるアセトアルデヒド、ホルムアルデヒド、アクロレインを比較するとアクロレインが最も強く、次いでホルムアルデヒドそしてアセトアルデヒドの順である。アクロレインの細胞毒性は、活性酸素の要因となりうる過酸化水素に比べても非常に強いことが報告されている（Kenneth Ramos、etal、Toxicology and Applied Pharmacology、Vol.95、61-71 (1988)）。 Acrolein and 4-hydroxynonenal are highly reactive with α, β-unsaturated aldehydes and are related to protein (enzyme and collagen) denaturation and cytotoxicity, and their cytotoxicity is compared with related aldehydes such as acetaldehyde, formaldehyde and acrolein. Acrolein is the strongest, followed by formaldehyde and acetaldehyde. It has been reported that the cytotoxicity of acrolein is much stronger than hydrogen peroxide, which can be a cause of active oxygen (Kenneth Ramos, etal, Toxicology and Applied Pharmacology, Vol. 95, 61-71 (1988)). .
アクロレインは、生体内ではポリアミンから生成することが（Gunnar Houen、etal、Acta Chemia Scandinavica、Vol.48、52-60 (1994)）知られており、また、アクロレインや４−ヒドロキシノネナールは、脂質の過酸化反応の過程で生成する（内田浩二、日本油化学会誌、Vol.47、No.11、29-37（1998））ことが知られている。また、アクロレインや４−ヒドロキシノネナールはプラスティックの燃焼、たばこの煙の中に存在したり、排気ガスや油脂の加熱によって生成される環境汚染物質の一つである。
そして、アクロレインから生体を守る検討では、ポリアミンにポリアミンオキシダーゼが作用しアクロレインを生成することから、ポリアミンオキシダーゼを阻害する特許(特開２００２−２８１９９９)とリポキシゲナーゼによる酸化過程でアクロレインが生成することからリポキシゲナーゼを阻害する特許(特開２００２-１３８０１３)が提示されている。しかし、これらによってアクロレインの生成が完全に抑えられるものではなく、たばこの煙の中のアクロレインのような場合は、生成過程を抑えるのではなく、既に生成されたアクロレインを直接捕捉する作用を持つ成分が望まれている。
And in the examination which protects a living body from acrolein, since polyamine oxidase acts on polyamine and acrolein is generated, acrolein is generated in the oxidation process by lipoxygenase and a patent (JP 2002-281999) that inhibits polyamine oxidase. A patent (Japanese Patent Application Laid-Open No. 2002-138013) is proposed. However, the production of acrolein is not completely suppressed by these, and in the case of acrolein in cigarette smoke, it does not suppress the production process, but has a function of directly capturing acrolein already produced Is desired.
本発明の課題は、既に生成されたアクロレインや４−ヒドロキシノネナールを直接捕捉する作用を有する成分、つまり、アクロレインや４−ヒドロキシノネナールと生体内のタンパク質との付加体形成を阻害する阻害剤、及びそれを含有する皮膚抗老化外用剤や抗老化用飲食品の提供である。 An object of the present invention is to provide a component having an action of directly capturing acrolein or 4-hydroxynonenal that has already been generated, that is, an inhibitor that inhibits adduct formation between acrolein or 4-hydroxynonenal and an in vivo protein, and It is providing the skin anti-aging external preparation and anti-aging food / beverage products containing it.
本発明者等は、このような課題を解決するために鋭意研究を重ねた結果、カテキン、没食子酸及びその誘導体、カフェイン酸、グルタチオン、チオプロリン、チオタウリン及びシステインが、アクロレインや４−ヒドロキシノネナールと生体内のタンパク質との付加体形成する過程を阻害するという作用を見出すことで本発明を完成するに至った。 As a result of intensive studies to solve such problems, the present inventors have found that catechin, gallic acid and its derivatives, caffeic acid, glutathione, thioproline, thiotaurine and cysteine are acrolein and 4-hydroxynonenal. The present invention has been completed by finding the action of inhibiting the process of forming adducts with proteins in the living body.
本発明によれば、生体内で生成したアクロレインがタンパク質と付加体を形成する反応を抑えることによるアクロレイン不加体形成抑制剤であるカテキン、没食子酸及びその誘導体、カフェイン酸、グルタチオン、チオプロリン、チオタウリン及びシステインを皮膚外用剤及び飲食品に含有させることにより、安全性の高い皮膚抗老化外用剤および抗老化用飲食品の提供が可能となり、皮膚抗老化外用剤に関してはシワ、タルミ等の発生を抑制する効果、抗老化用飲食品に関しては生体中の動脈硬化を抑制する効果をそれぞれ有することを可能とした。 According to the present invention, acrolein non-adduct formation inhibitor catechin, gallic acid and its derivatives, caffeic acid, glutathione, thioproline, acrolein non-adduct formation inhibitor by suppressing the reaction in which acrolein generated in vivo forms an adduct with a protein. By including thiotaurine and cysteine in skin external preparations and foods and drinks, it is possible to provide highly safe skin anti-aging external preparations and anti-aging foods and drinks. With regard to the effect of suppressing the anti-aging and food and drink for anti-aging, it was possible to have the effect of suppressing arteriosclerosis in the living body.
本発明におけるアクロレインを直接捕捉する方法は、内田らのアセチルリジンとアクロレインの付加生成物をHPLCで測定する方法（J.Biol.Chem.、Vol.273、No.26、Issue of June26、16058-16066(1998)）を改変して行った。本発明では、アクロレインとアセチルリジンとの反応で評価を行っているが、４−ヒドロキシノネナールとリジンに関しても同様な反応が起こることが分かっていることから本発明は４−ヒドロキシノネナールとの付加体形成にも有効である。 The method of directly capturing acrolein in the present invention is a method of measuring an addition product of acetyllysine and acrolein by Uchida et al. (J. Biol. Chem., Vol. 273, No. 26, Issue of June 26, 16058- 16066 (1998)). In the present invention, the evaluation is performed by the reaction of acrolein and acetyl lysine. However, since it is known that the same reaction occurs with respect to 4-hydroxynonenal and lysine, the present invention is an adduct with 4-hydroxynonenal. It is also effective for formation.
すなわち、0.1Mリン酸緩衝液（pH7.4）に100mMのN-アセチルリジンを溶解し、同様に0.1Mリン酸緩衝液（pH7.4）に10mMのアクロレインを溶解し、それぞれ450μLずつ取り、37℃で24時間反応させる。そこに被検試料を100μL加えて、反応液をHPLCで分析し、アクロレインとN-アセチルリジンの付加生成物を分析し、その生成量から抑制率を算出する。 Specifically, 100 mM N-acetyllysine was dissolved in 0.1 M phosphate buffer (pH 7.4), 10 mM acrolein was dissolved in 0.1 M phosphate buffer (pH 7.4), and 450 μL each was taken. React at 37 ° C for 24 hours. 100 μL of a test sample is added thereto, the reaction solution is analyzed by HPLC, the addition product of acrolein and N-acetyllysine is analyzed, and the inhibition rate is calculated from the amount of the product.
本発明における被検試料は、アクロレインがタンパク質との付加体を生成する過程を抑制するアクロレイン付加体生成抑制剤であり、カテキン、没食子酸及びその誘導体、カフェイン酸、グルタチオン、チオプロリン、チオタウリン及びシステインの少なくとも一種を含有させたことを特徴とする。 The test sample in the present invention is an acrolein adduct formation inhibitor that suppresses the process of acrolein forming an adduct with a protein. Catechin, gallic acid and its derivatives, caffeic acid, glutathione, thioproline, thiotaurine and cysteine It is characterized by containing at least one of the above.
また、本発明は、カテキン、没食子酸及びその誘導体、カフェイン酸、グルタチオン、チオプロリン、チオタウリン及びシステインの少なくとも一種または二種以上を含有させた皮膚抗老化外用剤および抗老化用飲食品である。 Moreover, this invention is a skin anti-aging external preparation and anti-aging food / beverage products containing at least 1 type or 2 types or more of catechin, gallic acid, its derivative (s), caffeic acid, glutathione, thioproline, thiotaurine, and cysteine.
本発明に使用する「カテキン」、「没食子酸及びその誘導体」、「カフェイン酸」、「グルタチオン」、「チオプロリン」、「チオタウリン」及び「システイン」は、工業原料をそのまま使用することもできるが、これらの化合物を含有する動植物エキスをそのまま使用することも、精製したものもを使用することもできる。 “Catechin”, “gallic acid and its derivatives”, “caffeic acid”, “glutathione”, “thioproline”, “thiotaurine” and “cysteine” used in the present invention may be industrial raw materials as they are. The animal and plant extracts containing these compounds can be used as they are, or purified ones can be used.
カテキンは、多量に含有する茶、ガンビールやリンゴ、ブドウ、カキ等に含まれる。没食子酸は、五倍子（ヌルデの虫こぶ）、ハマメリス、樫の樹皮など多くの植物に含まれる。カフェイン酸は、コーヒー中にクロロゲン酸として配糖体の形で存在する。グルタチオンは、酵母エキス中に多く含まれる。チオプロリンは、タラなどを加熱することで生成することがわかっている。 Catechin is contained in tea, gun beer, apples, grapes, oysters and the like that are contained in large amounts. Gallic acid is found in many plants, such as pentaploids (nulde bugs), hamamelis and birch bark. Caffeic acid is present in coffee as chlorogenic acid in the form of glycosides. Glutathione is abundant in yeast extract. Thioproline is known to be produced by heating cod and the like.
即ち、本発明に係る化合物を得るための精製法は、まず、水や各種極性有機溶媒及びそれらの混液を用いて抽出を行い、次いで、様々な方法を用いて精製される。各種イオン交換樹脂を用いる方法や各種活性炭、スチレン−ジビニルベンゼン系合成吸着剤（ＨＰ−２０：三菱化成社製）、オクタデシルシラン処理シリカ（Ｃｈｒｏｍａｔｏｒｅｘ ＯＤＳ：富士シリシア化学製）により吸着させ、適当な溶媒で溶出する方法が簡便でかつ実用的である。 That is, in the purification method for obtaining the compound according to the present invention, first, extraction is performed using water, various polar organic solvents and a mixture thereof, and then purification is performed using various methods. Adsorbed by various ion exchange resins, activated carbon, styrene-divinylbenzene synthetic adsorbent (HP-20: manufactured by Mitsubishi Kasei), octadecylsilane-treated silica (Chromatorex ODS: manufactured by Fuji Silysia Chemical), and suitable solvent The method of eluting with is simple and practical.
また、本発明に係る化合物の各種皮膚外用剤に対する配合量は、皮膚外用剤の実施態様、皮膚外用剤の使用形態等に応じて変動させることができるので特に限定されない。原則的には、有効量存在すれば良いことになるが、一般的には組成物中、乾燥重量に換算して０．０００１〜１００．０質量％が利用でき、好ましくは０．０１〜１０．０質量％、更に好ましくは０．１〜５．０質量％である。特に、用時調製のパウダー状の製剤等は、この本願発明に係る抽出物が１００質量％を含めた高配合率で利用されることが想定できる。 Moreover, since the compounding quantity with respect to various skin external preparations of the compound which concerns on this invention can be fluctuate | varied according to the embodiment of a skin external preparation, the usage form of a skin external preparation, etc., it is not specifically limited. In principle, an effective amount may be present, but generally 0.0001 to 100.0% by mass in terms of dry weight can be used in the composition, preferably 0.01 to 10%. 0.0 mass%, more preferably 0.1-5.0 mass%. In particular, it can be assumed that the powdery preparation prepared at the time of use is used at a high blending rate including 100% by mass of the extract according to the present invention.
本発明に係る皮膚外用剤の適用範囲は、特に限定されない。つまり、この発明の有効成分が有する作用効果に応じて各作用効果を利用できる全ての皮膚外用剤に適用できる。 The application range of the external preparation for skin according to the present invention is not particularly limited. That is, the present invention can be applied to all external preparations for skin that can use each function and effect according to the function and effect of the active ingredient of the present invention.
例えば、本発明に係る有効成分を各種皮膚外用剤基剤等に配合して、クリーム、乳液、化粧水、パック剤、洗顔料等に対して適用できる。また、前記各種皮膚外用剤の実施態様は、ローション、エマルジョン、軟膏、ゾル、ゲル、パウダー、スプレー、固形等の各種態様で適用できる。 For example, the active ingredient according to the present invention can be blended in various skin external preparation bases and applied to creams, emulsions, lotions, packs, face wash, and the like. Moreover, the various skin external preparations can be applied in various forms such as lotion, emulsion, ointment, sol, gel, powder, spray, and solid.
また、本発明に係る化合物の抗老化用飲食品に対する配合量は、抗老化用飲食品の実施態様、抗老化用飲食品の使用形態等に応じて変動させることができるので特に限定されない。原則的には、有効量存在すれば良いことになるが、一般的には組成物中、乾燥重量に換算して０．０００１〜１０．０質量％が利用でき、好ましくは０．０１〜５．０質量％、更に好ましくは０．１〜１．０質量％である。 Moreover, since the compounding quantity with respect to the anti-aging food / beverage products of the compound which concerns on this invention can be fluctuate | varied according to the embodiment of the anti-aging food / beverage products, the usage pattern of the anti-aging food / beverage products, it is not specifically limited. In principle, an effective amount may be present, but generally 0.0001 to 10.0% by mass in terms of dry weight can be used in the composition, preferably 0.01 to 5%. 0.0 mass%, more preferably 0.1-1.0 mass%.
本発明に係る抗老化用飲食品の適用範囲は、特に限定されない。つまり、この発明の有効成分が有する作用効果に応じて各作用効果を利用できる全ての抗老化用飲食品に適用できる。 The application range of the anti-aging food and drink according to the present invention is not particularly limited. That is, the present invention can be applied to all anti-aging foods and drinks that can use each function and effect according to the function and effect of the active ingredient of the present invention.
例えば、本発明に係る抗老化用飲食品は、ドリンク剤、ジェル状、粉末製剤、錠剤等の各種態様で適用できる。 For example, the anti-aging food and drink according to the present invention can be applied in various forms such as drinks, gels, powder formulations, tablets and the like.
以下、実施例により本発明を詳細に説明するが、本発明はこれらに限定されるものではない。 EXAMPLES Hereinafter, although an Example demonstrates this invention in detail, this invention is not limited to these.
〔実施例１〕
本実施例は、本発明のアクロレインとN−アセチルリジンとの付加体形成阻害剤について、具体的な抽出例を示したものである。
[Example 1]
This example shows a specific extraction example of the adduct formation inhibitor of acrolein and N-acetyllysine of the present invention.
被検体としては、試薬として市販されているビタミンC、エピカテキン、エピカテキンガレート、エピガロカテキンガレート、没食子酸、没食子酸プロピル、グルタチオン、チオプロリン、チオタウリン、L−システイン、L−シスチン、カフェイン酸、プロカテク酸、p−ヒドロキシ安息香酸、ゲンチシン酸、クエルセチン、ルチン、ミリシトリン及びナリンゲニンを用いた。 Samples include vitamin C, epicatechin, epicatechin gallate, epigallocatechin gallate, gallic acid, propyl gallate, glutathione, thioproline, thiotaurine, L-cysteine, L-cystine, caffeic acid, which are commercially available as reagents. Procatechuic acid, p-hydroxybenzoic acid, gentisic acid, quercetin, rutin, myricitrin and naringenin were used.
〔実施例２〕
本実施例は、本発明のアクロレインとN-アセチルリジンとの付加体形成阻害剤について、抑制効果を試験したものである。
〔実験例３〕アクロレインとN-アセチルリジンの付加体形成阻害率の測定
（１）実験方法
50mM N-アセチルリジン４５０μL（５０mMPBS（pH７.４））、１０mMアクロレイン４５０μL（５０ｍＭＰＢＳ（ｐＨ７.４））、試料１００μLを混合し、３７℃で２４時間放置後、HPLCで分析を行った。陽性対照として、類似の反応と思われる糖とアミノ酸やタンパク質と起こるメイラード反応の阻害剤としてとして知られるアミノグアニジンを用いて比較を行った。試料濃度は１０ｍM、５ｍMの溶液を用いて行った。
[Example 2]
In this example, the inhibitory effect of the adduct formation inhibitor of acrolein and N-acetyllysine of the present invention was tested.
[Experimental Example 3] Measurement of adduct formation inhibition rate of acrolein and N-acetyllysine (1) Experimental method
450 μL of 50 mM N-acetyllysine (50 mM PBS (pH 7.4)), 450 μL of 10 mM acrolein (50 mM PBS (pH 7.4)), and 100 μL of the sample were mixed and allowed to stand at 37 ° C. for 24 hours, and then analyzed by HPLC. As a positive control, a comparison was made using aminoguanidine, which is known as an inhibitor of the Maillard reaction that occurs with sugars and amino acids and proteins that appear to be similar reactions. The sample concentration was 10 mM and 5 mM.
（２）ＨＰＬＣ条件
・カラム：ＤＡＩＳＯＰＡＫ-ＳＰ１２０ ＯＤＳ-ＢＰ（１５0ｍｍ×６ｍｍ）
・温度：室温
・移動相：５％ＭｅＯＨ ｉｎ ０.１％ＴＦＡ
・検出：ＵＶ２２７ｎｍ
・注入量：５μＬ
・流量：１.５ｍＬ/ｍｉｎ
(2) HPLC conditions / column: DAISOPAK-SP120 ODS-BP (150 mm × 6 mm)
-Temperature: Room temperature-Mobile phase: 5% MeOH in 0.1% TFA
・ Detection: UV227nm
・ Injection volume: 5μL
・ Flow rate: 1.5mL / min
表１にアクロレイン付加体形成阻害作用効果（抑制率）を示す。 Table 1 shows the acrolein adduct formation inhibitory effect (suppression rate).
表１の結果より、カテキン、没食子酸及びその誘導体、カフェイン酸、グルタチオン、チオプロリン、チオタウリン及びシステインのアクロレインとN-アセチルリジンとの付加体の形成を阻害する作用が強いことを確認した。 From the results in Table 1, it was confirmed that catechin, gallic acid and its derivatives, caffeic acid, glutathione, thioproline, thiotaurine, and cysteine have strong effects of inhibiting the formation of adducts of acrolein and N-acetyllysine.
以下に本発明の処方例を挙げる。
＜処方例１＞化粧水
（成分名） （質量％）
エピカテキン ０．１
ヒアルロン酸Ｎａ ０．０１
グリセリン ５．０
ポリオキシエチレンソルビタンモノラウレート（２０Ｅ．０） １．５
エタノール ８．０
クエン酸トリエチル ２．０
防腐剤・酸化防止剤 適量
精製水 残部
The formulation example of this invention is given to the following.
<Formulation example 1> lotion (component name) (mass%)
Epicatechin 0.1
Hyaluronic acid Na 0.01
Glycerin 5.0
Polyoxyethylene sorbitan monolaurate (20E.0) 1.5
Ethanol 8.0
Triethyl citrate 2.0
Preservative / Antioxidant
Purified water balance
＜処方例２＞化粧用クリーム
（成分名） （質量％）
チオタウリン ５．０
ミツロウ ２．０
ステアリルアルコール ５．０
ステアリン酸 ８．０
スクワラン １０．０
自己乳化型グリセリルモノステアレート ３．０
ポリオキシエチレンセチルエーテル（２０Ｅ．０） １．０
グリセリン ５．０
水酸化カリウム ０．３
香料 適量
防腐剤・酸化防止剤 適量
精製水 残部
<Formulation example 2> Cosmetic cream (component name) (mass%)
Thiotaurine 5.0
Beeswax 2.0
Stearyl alcohol 5.0
Stearic acid 8.0
Squalane 10.0
Self-emulsifying glyceryl monostearate 3.0
Polyoxyethylene cetyl ether (20E.0) 1.0
Glycerin 5.0
Potassium hydroxide 0.3
Perfume Appropriate amount of preservative / antioxidant Appropriate amount of purified water
＜処方例３＞乳液
（成分名） （質量％）
没食子酸 ０．０１
スクワラン ８．０
ワセリン ２．０
ミツロウ ０．５
ソルビタンセスキオレエート ０．８
ポリオキシエチレンオレイルエーテル（２０Ｅ．０） １．２
カルボキシビニルポリマー ０．２
グリセリン １．５
水酸化カリウム ０．１
エタノール ７．０
香料 適量
防腐剤・酸化防止剤 適量
精製水 残部
<Prescription Example 3> Emulsion (component name) (mass%)
Gallic acid 0.01
Squalane 8.0
Vaseline 2.0
Beeslow 0.5
Sorbitan sesquioleate 0.8
Polyoxyethylene oleyl ether (20E.0) 1.2
Carboxyvinyl polymer 0.2
Glycerin 1.5
Potassium hydroxide 0.1
Ethanol 7.0
Perfume Appropriate amount of preservative / antioxidant Appropriate amount of purified water
＜処方例４＞パック剤
（成分名） （質量％）
チオプロリン ０．０００１
酢酸ビニル樹脂エマルジョン １５．０
ポリビニルアルコール １０．０
ホホバ油 ３．０
グリセリン ５．０
酸化チタン ８．０
カオリン ７．０
エタノール ５．０
香料 適量
防腐剤・酸化防止剤 適量
精製水 残部
<Prescription Example 4> Packing agent (component name) (mass%)
Thioproline 0.0001
Vinyl acetate resin emulsion 15.0
Polyvinyl alcohol 10.0
Jojoba oil 3.0
Glycerin 5.0
Titanium oxide 8.0
Kaolin 7.0
Ethanol 5.0
Perfume Appropriate amount of preservative / antioxidant Appropriate amount of purified water
＜処方例５＞軟膏
（成分名） （質量％）
没食子酸プロピル １０．０
酢酸トコフェロール ０．５
パラジメチルアミノ安息香酸オクチル ４．０
ブチルメトキシベンゾイルメタン ４．０
ステアリルアルコール １８．０
モクロウ ２０．０
グリセリンモノステアリン酸エステル ０．３
ワセリン ３３．０
香料 適量
防腐剤・酸化防止剤 適量
精製水 残部
<Prescription Example 5> Ointment (component name) (mass%)
Propyl gallate 10.0
Tocopherol acetate 0.5
Octyl paradimethylaminobenzoate 4.0
Butylmethoxybenzoylmethane 4.0
Stearyl alcohol 18.0
Owl 20.0
Glycerin monostearate 0.3
Vaseline 33.0
Perfume Appropriate amount of preservative / antioxidant Appropriate amount of purified water
＜処方例６＞ドリンク剤Ｉ
茶カテキン １．０
クエン酸 ０．１
ビタミンC 適量
精製水 残部
<Formulation Example 6> Drink I
Tea catechin 1.0
Citric acid 0.1
Vitamin C appropriate amount purified water balance
＜処方例７＞ドリンク剤II
システイン ０．１
クエン酸 ０．１
ビタミンC 適量
精製水 残部
<Prescription Example 7> Drink II
Cysteine 0.1
Citric acid 0.1
Vitamin C appropriate amount purified water balance
＜処方例８＞粉末製剤
カフェイン酸 ５．０
卵殻カルシウム １０．０
乳糖 １５．０
セルロース
残部
<Prescription Example 8> Powder Caffeic Acid 5.0
Eggshell calcium 10.0
Lactose 15.0
cellulose
The rest
＜処方例９＞錠剤
グルタチオン １０．０
卵殻カルシウム １０．０
乳糖 ２０．０
澱粉 ７．０
デキストリン ８．０
硬化油 ５．０
セルロース
残部
<Prescription Example 9> Tablet Glutathione 10.0
Eggshell calcium 10.0
Lactose 20.0
Starch 7.0
Dextrin 8.0
Hardened oil 5.0
cellulose
The rest
本発明によれば、生体内で生成したアクロレインがタンパク質と付加体を形成する反応を抑制する作用を有するカテキン、没食子酸及びその誘導体、グルタチオン、チオプロリン、チオタウリン及びシステインを含有することにより、安全性の高い皮膚抗老化外用剤や抗老化用飲食品に応用が期待できる。 According to the present invention, acrolein produced in vivo contains catechin, gallic acid and its derivatives, glutathione, thioproline, thiotaurine, and cysteine, which have an action of suppressing the reaction of forming an adduct with a protein. It can be expected to be applied to skin anti-aging external preparations and foods for anti-aging.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006195358A JP5063947B2 (en) | 2006-07-18 | 2006-07-18 | Acrolein adduct formation inhibitor, and skin anti-aging external preparation and anti-aging food and drink containing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006195358A JP5063947B2 (en) | 2006-07-18 | 2006-07-18 | Acrolein adduct formation inhibitor, and skin anti-aging external preparation and anti-aging food and drink containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008024600A true JP2008024600A (en) | 2008-02-07 |
| JP5063947B2 JP5063947B2 (en) | 2012-10-31 |
Family
ID=39115612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006195358A Active JP5063947B2 (en) | 2006-07-18 | 2006-07-18 | Acrolein adduct formation inhibitor, and skin anti-aging external preparation and anti-aging food and drink containing the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5063947B2 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010077123A (en) * | 2008-08-29 | 2010-04-08 | Hayashikane Sangyo Kk | Maillard reaction inhibitor |
| JP2011236191A (en) * | 2010-05-11 | 2011-11-24 | Shunzo Kobayashi | Arteriosclerosis improving agent |
| WO2016063991A1 (en) * | 2014-10-24 | 2016-04-28 | 株式会社資生堂 | Beauty care method for improving skin condition caused by reduction or increase in corneocyte desquamation, and evaluation method |
| JP2018002631A (en) * | 2016-06-30 | 2018-01-11 | 株式会社アンチエイジングコミュニケーション | Oph active enhancer |
| WO2020040621A1 (en) * | 2018-08-23 | 2020-02-27 | 주식회사 엘지생활건강 | Composition for promoting differentiation or proliferation of human adipose stem cells |
| CN114931202A (en) * | 2022-04-21 | 2022-08-23 | 东莞思朗食品有限公司 | Method for reducing glyoxal and formaldehyde in food, adduct generated by method and detection method |
| CN115530314A (en) * | 2022-10-14 | 2022-12-30 | 南京师范大学 | Application of disodium 5 '-inosinate and disodium 5' -guanylate as acrolein inhibitor |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112273385B (en) * | 2020-11-25 | 2021-07-23 | 宿迁市产品质量监督检验所 | Application of adducted product of octyl gallate and acrolein in preparation of bacteriostatic agent |
Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03275613A (en) * | 1990-03-23 | 1991-12-06 | Kose Corp | Skin external agent |
| JPH0665044A (en) * | 1992-08-17 | 1994-03-08 | Kose Corp | Skin external preparation |
| JPH06128142A (en) * | 1992-10-16 | 1994-05-10 | Kose Corp | External agent for skin |
| JPH0748241A (en) * | 1993-05-07 | 1995-02-21 | L'oreal Sa | Method to apply glutathione alkyl ester to make-up composition or composition for skin of which purpose is local treatment for aging of skin |
| JPH1059839A (en) * | 1996-08-21 | 1998-03-03 | Noevir Co Ltd | Preparation for external use for skin |
| JPH10130255A (en) * | 1996-11-01 | 1998-05-19 | Pola Chem Ind Inc | Antioxidant |
| JPH10330244A (en) * | 1997-03-30 | 1998-12-15 | Shiseido Co Ltd | External composition for preventing environmental stress |
| JPH11137212A (en) * | 1997-11-14 | 1999-05-25 | Sogo Pharmaceut Co Ltd | Beauty culture composition |
| JPH11263720A (en) * | 1998-03-13 | 1999-09-28 | Shiseido Co Ltd | Antiaging agent |
| JP2000319154A (en) * | 1999-05-06 | 2000-11-21 | Nippon Menaade Keshohin Kk | Phototoxicity inhibitor |
| JP2002138013A (en) * | 2000-10-27 | 2002-05-14 | Pias Arise Kk | Hne-and-acrolein formation inhibiting and hne-and- acrolein decomposition promoting agent, and skin aging care preparation for external use |
| JP2002255803A (en) * | 2001-03-05 | 2002-09-11 | Nippon Menaade Keshohin Kk | Phototoxicity inhibitor comprising extract from tussilago farfara l. |
| JP2003267992A (en) * | 2002-03-18 | 2003-09-25 | Makoto Fujii | Antioxidant, aging prevention and/or anticancer agent |
| JP2004091376A (en) * | 2002-08-30 | 2004-03-25 | Naris Cosmetics Co Ltd | Epidermis keratinization normalizing agent and skin care preparation for external use for skin containing the same |
| JP2004161701A (en) * | 2002-11-14 | 2004-06-10 | Kobayashi Pharmaceut Co Ltd | Composition in which bitterness and odor of cysteines are reduced |
| JP2006160630A (en) * | 2004-12-03 | 2006-06-22 | Naris Cosmetics Co Ltd | Acrolein adduct formation inhibitor, external preparation for skin containing the same, and healthy supplement food |
-
2006
- 2006-07-18 JP JP2006195358A patent/JP5063947B2/en active Active
Patent Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03275613A (en) * | 1990-03-23 | 1991-12-06 | Kose Corp | Skin external agent |
| JPH0665044A (en) * | 1992-08-17 | 1994-03-08 | Kose Corp | Skin external preparation |
| JPH06128142A (en) * | 1992-10-16 | 1994-05-10 | Kose Corp | External agent for skin |
| JPH0748241A (en) * | 1993-05-07 | 1995-02-21 | L'oreal Sa | Method to apply glutathione alkyl ester to make-up composition or composition for skin of which purpose is local treatment for aging of skin |
| JPH1059839A (en) * | 1996-08-21 | 1998-03-03 | Noevir Co Ltd | Preparation for external use for skin |
| JPH10130255A (en) * | 1996-11-01 | 1998-05-19 | Pola Chem Ind Inc | Antioxidant |
| JPH10330244A (en) * | 1997-03-30 | 1998-12-15 | Shiseido Co Ltd | External composition for preventing environmental stress |
| JPH11137212A (en) * | 1997-11-14 | 1999-05-25 | Sogo Pharmaceut Co Ltd | Beauty culture composition |
| JPH11263720A (en) * | 1998-03-13 | 1999-09-28 | Shiseido Co Ltd | Antiaging agent |
| JP2000319154A (en) * | 1999-05-06 | 2000-11-21 | Nippon Menaade Keshohin Kk | Phototoxicity inhibitor |
| JP2002138013A (en) * | 2000-10-27 | 2002-05-14 | Pias Arise Kk | Hne-and-acrolein formation inhibiting and hne-and- acrolein decomposition promoting agent, and skin aging care preparation for external use |
| JP2002255803A (en) * | 2001-03-05 | 2002-09-11 | Nippon Menaade Keshohin Kk | Phototoxicity inhibitor comprising extract from tussilago farfara l. |
| JP2003267992A (en) * | 2002-03-18 | 2003-09-25 | Makoto Fujii | Antioxidant, aging prevention and/or anticancer agent |
| JP2004091376A (en) * | 2002-08-30 | 2004-03-25 | Naris Cosmetics Co Ltd | Epidermis keratinization normalizing agent and skin care preparation for external use for skin containing the same |
| JP2004161701A (en) * | 2002-11-14 | 2004-06-10 | Kobayashi Pharmaceut Co Ltd | Composition in which bitterness and odor of cysteines are reduced |
| JP2006160630A (en) * | 2004-12-03 | 2006-06-22 | Naris Cosmetics Co Ltd | Acrolein adduct formation inhibitor, external preparation for skin containing the same, and healthy supplement food |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010077123A (en) * | 2008-08-29 | 2010-04-08 | Hayashikane Sangyo Kk | Maillard reaction inhibitor |
| JP2011236191A (en) * | 2010-05-11 | 2011-11-24 | Shunzo Kobayashi | Arteriosclerosis improving agent |
| WO2016063991A1 (en) * | 2014-10-24 | 2016-04-28 | 株式会社資生堂 | Beauty care method for improving skin condition caused by reduction or increase in corneocyte desquamation, and evaluation method |
| JPWO2016063991A1 (en) * | 2014-10-24 | 2017-08-31 | 株式会社 資生堂 | Beauty method and evaluation method for improving skin condition caused by suppression or enhancement of stratum corneum peeling |
| JP2018002631A (en) * | 2016-06-30 | 2018-01-11 | 株式会社アンチエイジングコミュニケーション | Oph active enhancer |
| WO2020040621A1 (en) * | 2018-08-23 | 2020-02-27 | 주식회사 엘지생활건강 | Composition for promoting differentiation or proliferation of human adipose stem cells |
| CN114931202A (en) * | 2022-04-21 | 2022-08-23 | 东莞思朗食品有限公司 | Method for reducing glyoxal and formaldehyde in food, adduct generated by method and detection method |
| CN115530314A (en) * | 2022-10-14 | 2022-12-30 | 南京师范大学 | Application of disodium 5 '-inosinate and disodium 5' -guanylate as acrolein inhibitor |
| CN115530314B (en) * | 2022-10-14 | 2024-04-19 | 南京师范大学 | Application of disodium 5 '-inosinate and disodium 5' -guanylate as acrolein inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5063947B2 (en) | 2012-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5063947B2 (en) | Acrolein adduct formation inhibitor, and skin anti-aging external preparation and anti-aging food and drink containing the same | |
| CN104114176A (en) | Maillard reaction inhibitor | |
| JP2014028814A (en) | Deglycation of age | |
| KR102442117B1 (en) | Cosmetic composition for skin improvement comprising Orostachys japonicus extract or mixture of Orostachys japonicus extract and Pachymeniopsis elliptica extract | |
| JP2006273811A (en) | Maillard reaction inhibitor | |
| JP3502415B2 (en) | Maillard reaction inhibitor | |
| JP2008074788A (en) | Elastin production promoter | |
| JPH08259431A (en) | Maillard reaction inhibitor and dermal preparation for external use containing the same | |
| JP5039314B2 (en) | Acrolein adduct formation inhibitor, and external preparation for skin and food and drink containing the same | |
| JP2008024601A (en) | Inhibitor for acrolein adduct formation, skin anti-aging external preparation and anti-aging food and beverage containing the same | |
| JP4676448B2 (en) | Proteolytic enzyme inhibitor enhancement agent and skin moisture retention improver containing the same | |
| JP4866012B2 (en) | Acrolein adduct formation inhibitor, skin external preparation and health supplement containing the same | |
| JP4944372B2 (en) | Acrolein adduct formation inhibitor, and skin external preparation and health supplement containing the same | |
| JP2002179592A (en) | Composition for removing abnormal protein | |
| JP5380649B2 (en) | Milk component hydrolyzate | |
| KR101904501B1 (en) | Cosmetic compositions for improving skin wrinkles or skin elasticity comprising fucosterol | |
| JP2017071568A (en) | Skin external preparation, anti-glycation agent and collagenase inhibitor | |
| WO2009155097A1 (en) | Natural product inhibitors of 3dg | |
| JP5712429B2 (en) | Apolactoferrin-containing composition | |
| KR20170052556A (en) | Cosmetic compositions for improving skin aging or skin moisturizing comprising fucosterol | |
| KR101373191B1 (en) | Fermented microalgae for antioxidant effect and a functional product composition containing the same | |
| JP5004045B2 (en) | Antibacterial agent and antibacterial composition | |
| KR20140140338A (en) | Acai berry extracts for improving blood circulation and Hypertension and process for preparation thereof | |
| JP6047793B2 (en) | Enzyme activity inhibitor | |
| KR101661349B1 (en) | Composition with Antioxidation Function Containing ACQ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090717 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110516 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110614 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110811 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120410 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120704 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120711 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120807 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120808 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5063947 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150817 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |